Masitinib
Author: Michael Ramirez
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor receptor 3, platelet-derived growth factor receptor alpha/beta, lymphocyte-specific protein tyrosine kinase (Lck), Lck/Yes-related novel protein tyrosine kinase, and focal adhesion kinase. This makes the drug effective at controlling the survival, differentiation, and degranulation of mast cells, which are involved in oncogenic processes such as angiogenesis, tissue remodeling, and immunomodulation.
CONTENTS
5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 masitinib : Melanoma
17 masitinib : Prostate cancer
29 masitinib : Colorectal cancer (CRC)
43 masitinib : Pancreatic cancer
LIST OF FIGURES
10 Figure 8: Datamonitor Healthcare’s drug assessment summary for masitinib in colorectal cancer
11 Figure 20: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
13 Figure 19: Keytruda for colorectal cancer – SWOT analysis
22 Figure 21: Datamonitor Healthcare’s drug assessment summary for Keytruda in colorectal cancer
24 Figure 22: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer
28 Figure 23: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
34 Figure 1: Colorectal cancer – current and future market dynamics analysis
35 Figure 26: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
38 Figure 25: Datamonitor Healthcare’s drug assessment summary of OncoVAX for colon cancer
48 Figure 6: Patient-based forecast methodology for colorectal cancer
LIST OF TABLES
7 Table 1: Masitinib drug profile
8 Table 2: Masitinib pivotal late-phase clinical trial in melanoma
14 Table 3: Masitinib sales for melanoma across the five major EU markets, by country ($m), 2017–26
16 Table 4: Masitinib patient numbers for melanoma across the five major EU markets, by country, 2017–26
17 Table 5: Masitinib drug profile
103 Table 6: Masitinib Phase III trial in prostate cancer
21 Table 7: Masitinib Phase II data in prostate cancer
29 Table 8: Masitinib drug profile
31 Table 9: Masitinib Phase III trial in colorectal cancer
33 Table 10: Masitinib early-phase data in colorectal cancer
39 Table 11: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
41 Table 12: Patients treated with masitinib across the US and five major EU markets, by country, 2016–25
44 Table 13: Masitinib drug profile
45 Table 14: Masitinib Phase III data in pancreatic cancer
47 Table 42: Opdivo early-phase trials in colorectal cancer
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Imlygic 
Sign up to the